Roivant Sciences Ltd. (NASDAQ: ROIV) stock fell -1.81% on Wednesday to $9.22 against a previous-day closing price of $9.39. With 1.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.33 whereas the lowest price it dropped to was $9.05. The 52-week range on ROIV shows that it touched its highest point at $10.00 and its lowest point at $2.87 during that stretch. It currently has a 1-year price target of $14.00.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ROIV was up-trending over the past week, with a rise of 1.99%, but this was up by 5.49% over a month. Three-month performance surged to 12.17% while six-month performance rose 90.89%. The stock gained 152.60% in the past year, while it has gained 15.39% so far this year. A look at the trailing 12-month EPS for ROIV yields -1.78 with Next year EPS estimates of -1.35. For the next quarter, that number is -0.37. This implies an EPS growth rate of -6.80% for this year and 17.70% for next year.
Float and Shares Shorts:
At present, 713.32 million ROIV shares are outstanding with a float of 440.82 million shares on hand for trading. On Apr 27, 2023, short shares totaled 14.02 million, which was 1.85% higher than short shares on Mar 30, 2023. In addition to Mr. Matthew Gline as the firm’s CEO & Director, Dr. Eric Venker M.D., Pharm.D. serves as its Pres & COO.
Through their ownership of 53.39% of ROIV’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 5.80% of ROIV, in contrast to 48.04% held by mutual funds. Shares owned by individuals account for 42.27%. As the largest shareholder in ROIV with 16.16% of the stake, QVT Financial LP holds 122,541,536 shares worth 122,541,536. A second-largest stockholder of ROIV, Viking Global Investors LP, holds 88,238,700 shares, controlling over 11.63% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in ROIV, holding 30,762,284 shares or 4.06% stake.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Dec 30, 2022, ROIV reported revenue of $4.32M and operating income of -$282.31M. The EBITDA in the recently reported quarter was -$322.63M and diluted EPS was -$0.48.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ROIV since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ROIV analysts setting a high price target of $19.00 and a low target of $10.00, the average target price over the next 12 months is $14.00. Based on these targets, ROIV could surge 106.07% to reach the target high and rise by 8.46% to reach the target low. Reaching the average price target will result in a growth of 51.84% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.